Background: The presence of a chikungunya virus (CHIKV) outbreak could have an impact on transfusion safety when there are a large number of infected persons during an epidemic. Serosurveys have found that 3% to 28% of infected persons remain asymptomatic and are potential disseminators of transfusion-associated chikungunya. However, the viremic profiles of asymptomatic chikungunya patients, the major determinant of the transfusion risk, are unknown.
Study Design And Methods: Data on CHIKV viremic profiles were obtained from a case-control study carried out in a chikungunya-affected area during the 2009 epidemic in Songkhla, Thailand. CHIKV-infected individuals were classified based on a combination of the patient's history and clinical and laboratory findings.
Results: There were 134 laboratory-proven CHIKV-infected cases, of whom 122 (91.0%) were symptomatic and 12 (9.0%) were asymptomatic. The viremic levels in the symptomatic infected individuals peaked on the first 3 days and lasted up to 8 days as defined by viral isolates. CHIKV genomic products were detected as late as Day 17 of illness. The viral loads observed in the symptomatic individuals (median, 5.6 × 10(5) plaque-forming units per milliliter [pfu/mL]; range, 1.3 × 10(1) -2.9 × 10(8) pfu/mL) were higher than but not significantly different from those observed in the viremic asymptomatic individuals (median, 3.4 × 10(3) pfu/mL; range, 8.4 × 10(1) -2.9 × 10(5) pfu/mL [p = 0.22, Wilcoxon test]).
Conclusion: CHIKV infection is highly symptomatic and is associated with high-titred viremia. The viremic levels in asymptomatic CHIKV-infected individuals were in the range known to be capable of transmitting the disease to experimental animals. Asymptomatic CHIKV viremia individuals could be potential disseminators of transfusion-associated chikungunya.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1537-2995.2012.03960.x | DOI Listing |
Viruses
October 2024
Department of Public Health, Universitas Padjadjaran, Bandung 40161, Indonesia.
Semergen
October 2024
Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, España.
Objective: Undiagnosed viral hepatitis is an impediment to the elimination of viral hepatitis. Clinical Practice Guidelines (CPG) recommend screening in patients with hypertransaminasemia. The aim of the study was to evaluate the early detection of viral hepatitisB andC established in our health area in this population group.
View Article and Find Full Text PDFMed
October 2024
IrsiCaixa, Badalona, Spain; Germans Trias i Pujol Research Institute, Badalona, Spain; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain. Electronic address:
Biomark Res
October 2024
MRL, Merck & Co., Inc, Rahway, NJ, USA.
Background: Latency remains a major obstacle to finding a cure for HIV despite the availability of antiretroviral therapy. Due to virus dormancy, limited biomarkers are available to identify latent HIV-infected cells. Profiling of individual HIV-infected cells is needed to explore potential latency biomarkers and to study the mechanisms of persistence that maintain the HIV reservoir.
View Article and Find Full Text PDFPLoS One
September 2024
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Background: High HIV viral loads (VL) are associated with increased morbidity, mortality, and on-going transmission. HIV controllers maintain low VLs in the absence of antiretroviral therapy (ART). We previously used a massively multiplexed antibody profiling assay (VirScan) to compare antibody profiles in HIV controllers and persons living with HIV (PWH) who were virally suppressed on ART.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!